VEGFA and Alzheimer disease: Xenogeneic haMPCs were chosen because of some considerations: (1) Investigating the effect of haMPCs on osteoarthritis as a cell-therapy candidate in preclinical animal study; (2) The yielding of MPCs in an equal volume of lipoaspirates exceeds bone marrow aspirate by about 300-fold [14,32,33]; (3) In comparison to AD-MPCs, BM-MPCs showed higher expression of angiogenic markers, such as angiopoietin and vascular endothelial growth factor which exhibited inhibitive effect on OA cartilage regeneration [34]; and (4) Telomere length showed no compromise in AD-MPCs during aging [24].